The global Tumor Embolization Market is benefiting from advancements in interventional radiology and cancer treatment technologies. Tumor embolization has become a preferred option for managing selected cancers due to its precision and safety. Rising cancer prevalence continues to drive demand. According to The Insight Partners, the Tumor Embolization Market is expected to grow from...

The global CAR-T Cell Therapy Market is experiencing remarkable growth as innovative immunotherapy approaches continue to transform cancer treatment worldwide. Chimeric Antigen Receptor T-cell therapy represents one of the most significant breakthroughs in oncology, offering targeted treatment options for patients with certain hematologic malignancies and treatment-resistant cancers. By...

According to a new report from Intel Market Research, the global Brigatinib API market was valued at USD 42.5 million in 2025 and is projected to reach USD 89.7 million by 2034, growing at a robust CAGR of 8.1% during the forecast period (2026–2034). This growth is propelled by the increasing global incidence of non-small cell lung cancer, particularly ALK-positive cases among...

According to a new report from Intel Market Research, the global Crizotinib Drugs market was valued at USD 582.4 million in 2025 and is projected to reach USD 1,043.7 million by 2034, growing at a CAGR of 6.7% during the forecast period (2026–2034). This growth is propelled by the rising global incidence of lung cancer, increasing adoption of molecular diagnostic testing for genetic...

The global Epidermal Growth Factor Receptor (EGFR) inhibitor industry is witnessing substantial momentum due to the increasing prevalence of cancer, growing adoption of targeted therapies, and advancements in precision medicine. The Epidermal Growth Factor Receptor Inhibitor Market size is expected to reach US$ 32.14 Billion by 2034 from US$ 15.92 Billion in 2025. The market is estimated to...

According to a new report from Intel Market Research, the global Cabozantinib Drug market was valued at USD 2.12 billion in 2025 and is projected to reach USD 4.01 billion by 2034, growing at a robust CAGR of 7.5% during the forecast period (2026–2034). This growth is propelled by the escalating global burden of cancer, particularly renal and liver cancers, alongside expanding clinical...

According to a new report from Intel Market Research, the global Dual-Antibody ADC market was valued at USD 477 million in 2024 and is projected to reach USD 691 million by 2032, exhibiting a steady CAGR of 6.2% during the forecast period (2025–2032). This growth is driven by increasing cancer prevalence and demand for precision medicine, superior tumor targeting capabilities of...

According to a new report from Intel Market Research, the global Multi-target MET TKIs market was valued at USD 1.52 billion in 2025 and is projected to reach USD 3.18 billion by 2034, growing at a CAGR of 7.6% during the forecast period (2026–2034). This growth is propelled by the rising global incidence of non-small cell lung cancer and medullary thyroid cancer, precision oncology...

According to a new report from Intel Market Research, the global Selpercatinib Capsules market was valued at USD 420 million in 2025 and is projected to reach USD 820 million by 2034, growing at a CAGR of 7.8% during the forecast period (2026–2034). This growth is propelled by the increasing prevalence of RET-altered cancers, growing adoption of biomarker-driven therapies, and...

According to a new report from Intel Market Research, the global TKIs for Breast Cancer market was valued at USD 1.82 billion in 2025 and is projected to reach USD 3.74 billion by 2034, growing at a CAGR of 7.3% during the forecast period (2025–2034). This growth is propelled by the rising global incidence of breast cancer, growing adoption of precision oncology, and increasing regulatory...

The United States Antibody‑Drug Conjugate (ADC) for Solid Tumors market size was valued at approximately USD 0.55 billion in 2025. The market is projected to grow from approximately USD 0.58 billion in 2026 to around USD 1.04 billion by 2034, exhibiting a CAGR of about 8.9% during the forecast period. Antibody‑Drug Conjugates are targeted therapeutics that combine a monoclonal antibody that...